Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
TLSI Quote, Financials, Valuation and Earnings
Last price:
$5.02
Seasonality move
:
-4.22%
Day range:
$4.95 - $5.10
52-week range:
$3.42 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.15x
P/B ratio:
--
Volume:
137.5K
Avg. volume:
163.9K
1-year change:
-13.02%
Market cap:
$252.8M
Revenue:
$29.4M
EPS (TTM):
-$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$13.2M | -$0.13 | 46.37% | -67.11% | $11.75 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
ATEC
Alphatec Holdings, Inc.
|
$212.2M | $0.04 | 17.11% | -88.21% | $24.62 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.3% | 75.74% | $104.75 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$5.06 | $11.75 | $252.8M | -- | $0.00 | 0% | 4.15x |
|
ABT
Abbott Laboratories
|
$114.12 | $133.39 | $198.3B | 30.70x | $0.63 | 2.1% | 4.50x |
|
ARAY
Accuray, Inc.
|
$0.55 | $2.53 | $65.5M | 149.00x | $0.00 | 0% | 0.14x |
|
ATEC
Alphatec Holdings, Inc.
|
$13.47 | $24.62 | $2B | -- | $0.00 | 0% | 2.64x |
|
BSX
Boston Scientific Corp.
|
$76.22 | $104.75 | $113.1B | 39.31x | $0.00 | 0% | 5.67x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.6M | -- | $0.00 | 0% | 4.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
461.2% | -0.201 | 14.71% | 2.54x |
|
ABT
Abbott Laboratories
|
21.33% | 0.218 | 6.98% | 1.05x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.787 | 177.87% | 0.52x |
|
ATEC
Alphatec Holdings, Inc.
|
94.3% | 1.734 | 18.93% | 1.24x |
|
BSX
Boston Scientific Corp.
|
33.07% | 0.600 | 8.45% | 0.94x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$9.7M | -$9M | -936.41% | -- | -77.94% | -$3.9M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
ATEC
Alphatec Holdings, Inc.
|
$130.4M | -$5.4M | -23.65% | -1092.5% | -2.52% | $5.7M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
TriSalus Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns TLSI or ABT?
Abbott Laboratories has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 15.71%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About TLSI or ABT?
TriSalus Life Sciences, Inc. has a consensus price target of $11.75, signalling upside risk potential of 127.27%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 16.89%. Given that TriSalus Life Sciences, Inc. has higher upside potential than Abbott Laboratories, analysts believe TriSalus Life Sciences, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.5 0 0 ABTAbbott Laboratories16 7 0 -
Is TLSI or ABT More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.919%.
-
Which is a Better Dividend Stock TLSI or ABT?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.1% to investors and pays a quarterly dividend of $0.63 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TLSI or ABT?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Abbott Laboratories's net income of $1.8B. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 30.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.15x versus 4.50x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.15x -- $11.6M -$10.8M ABTAbbott Laboratories4.50x 30.70x $11.5B $1.8B
-
Which has Higher Returns TLSI or ARAY?
Accuray, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -13.47%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About TLSI or ARAY?
TriSalus Life Sciences, Inc. has a consensus price target of $11.75, signalling upside risk potential of 127.27%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 357.84%. Given that Accuray, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Accuray, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.5 0 0 ARAYAccuray, Inc.2 0 0 -
Is TLSI or ARAY More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.
-
Which is a Better Dividend Stock TLSI or ARAY?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or ARAY?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.15x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.15x -- $11.6M -$10.8M ARAYAccuray, Inc.0.14x 149.00x $102.2M -$13.8M
-
Which has Higher Returns TLSI or ATEC?
Alphatec Holdings, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -10.21%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ATECAlphatec Holdings, Inc.61.24% -$0.14 $632.1M -
What do Analysts Say About TLSI or ATEC?
TriSalus Life Sciences, Inc. has a consensus price target of $11.75, signalling upside risk potential of 127.27%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.74%. Given that TriSalus Life Sciences, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than Alphatec Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.5 0 0 ATECAlphatec Holdings, Inc.8 1 0 -
Is TLSI or ATEC More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.
-
Which is a Better Dividend Stock TLSI or ATEC?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or ATEC?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.15x versus 2.64x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.15x -- $11.6M -$10.8M ATECAlphatec Holdings, Inc.2.64x -- $212.9M -$21.7M
-
Which has Higher Returns TLSI or BSX?
Boston Scientific Corp. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 12.68%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About TLSI or BSX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.75, signalling upside risk potential of 127.27%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 37.43%. Given that TriSalus Life Sciences, Inc. has higher upside potential than Boston Scientific Corp., analysts believe TriSalus Life Sciences, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.5 0 0 BSXBoston Scientific Corp.25 0 0 -
Is TLSI or BSX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.
-
Which is a Better Dividend Stock TLSI or BSX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or BSX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Boston Scientific Corp.'s net income of $670M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.15x versus 5.67x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.15x -- $11.6M -$10.8M BSXBoston Scientific Corp.5.67x 39.31x $5.3B $670M
-
Which has Higher Returns TLSI or PSTV?
Plus Therapeutics, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -316.61%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About TLSI or PSTV?
TriSalus Life Sciences, Inc. has a consensus price target of $11.75, signalling upside risk potential of 127.27%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.5 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is TLSI or PSTV More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock TLSI or PSTV?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or PSTV?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.15x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.15x -- $11.6M -$10.8M PSTVPlus Therapeutics, Inc.4.85x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
36
WLDN alert for Mar 3
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is up 22.11% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
